ChromaDex Corp. (CDXC)

[bulldurham]

another comment to his SA
Gee, apparently you din't read my previous note.
I told you to at least read the article of Wikipedia before going into your new long,inaccurate tirade and diatribe on Dr.P.Frost.

Yes, Dr. Frost was one of the first and largest investors in Protalix BioTherapeutics, investing $24 million in the company that would later go on to develop an FDA-approved treatment for Gaucher disease.
And $24 million is not much, compared to his $33 million gift to the School of Music at the University of Miami, or the $35 millions towards the construction of the Miami Science Museum, or his donations to the Art Museum at FIU, or the millions he has donated to Scripps Florida.

He resigned from PLX's Board of Directors in 2007, and a 2010 U.S. Securities and Exchange Commission filing indicated that he donated around $8 million in Protalix shares to a charitable organization.

One thing that shorts like you don't take into account is that in the best case, you could never make more than a 80% profit, while been exposed all the time to a "margin call". On the other hand, people playing it from the "long side" could be able to make much more than 100% on their initial stake.
On PLX, for example, if you had sold it short at $45 and coveresd at $5 in 2007 (price adjusted for splits) you had made an 88.88% gain, (actually less than that, taking taking into account Regulation T).
But if you had bought it June 2009 and sold it in November 2009, you could have made more than a 1,800% gain on the LONG SIDE!!!
You could never have that kind of profit on the short side.
http://bit.ly/NsWfQ6;insttype=&fre...

Regarding OPKO and its OPK stock:
Yes, it is true that OPKO was initially focused on Ophthalmology, and the opthalmic instruments they bought from OTI are the best, according to several Ophthalmologists than I know that own more than one.
And it is also true that bevasiranib, was one of the top five most promising drugs entering Phase III clinical trials during the third quarter of 2007.
But like many other drugs, it was not able to meet its primary endpoint, and although preliminary data showed it had positive activity when used adjunctively with Gentech's Lucentis, OPKO decided to terminate its late-stage trial of Bevasiranib for the treatment of wet age-related macular degeneration in March 2009.

But that was also when Dr. P. Frost decided to enlarge OPKO's focus, and since then OPKO is no longer depending in one drug or one sector, since it is now a Health Care Company, with Pharmaceutical and Diagnostics Divisions, engaging in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico.
And from a "Technical" standpoint, in spite of this week's dip from the resistance at the $4.80 level, the stock remains on its longer term up-trend, which started in June 2009, when OPKO decided to enlarge its focus from just being "an Ophthalmology Company".
http://bit.ly/LqVimQ;insttype=&fre...
And my actual "average cost" on it is below $2, which still gives me a larger % gain than any that you could possibly obtain shorting this stock, or any other.
You say:
"Like Dr. Frost's predecessor company, Protalix, Opko's underlying products are worth far less than the current market capitalization, IN OUR OPINION."
I emphasize that last part, because i like to compare YOUR OPINION on shorting the stock, with Dr.Frost opinion, who has continued to buy OPKO's stock on a daily basis.
Comparing Protalix with OPKO is like comparing apples and oranges.

You said:
"We would not be the least bit surprised if Opko shareholders wake up one day and find that the share price has suddenly declined 50% or more."
And I think that I would not be surprised if OPK shares more than double in price, when some positive news comes out.
And there are quite a few possibilities for that in the near future.
Rolapitant is already on a PIII for nausea and vomiting in patients after anesthesia or receiving chemotherapy. The PIII shold not take long, it isn't costing OPKO any money, and GOOD RESULTS are very likely.
The PSA test in the CLAROS ANALYZER has already been approved in Europe, and OPKO has now licenced some biomarkers, which can significantly increase the reliability of that test, which could avoid 60% of biopsies now been performed on "false postive" results with the current PSA test. Be careful, because "News" on that could come out sooner than you think.
LabCorp is presently working on a Blood Test for AD, based on the biomarkers discovered by OPKO. That would be a commercially available test, something that was not possible with OPKO's low throughput microarray platform. It isn't costing OPKO any money, but you also better be ready when NEWS do come out.
There are also many other possible NEWS that could surprise you sooner than you apparently think, like results on a Blood Test for Neruromyelitis Optica; results on LCP6 on blood test for NSCLC; results from SR-3306 or other inhibitors of JNK on degenerative diseases,like Parkinson's,MS, ALS or AD.
Actually, I am as excited about OPKO's possible winning products, as I was back in 1967 when I bought Tool Research and Engeneering based on its "honeycomb" product for atenuation of the noise of the supersonic transport plane.
And TRE that year went from $3 to $90.
Try to accomplish that with your short selling. !!!
It also reminds me of Resorts International, which had evolved from Mary Carter Paints, (a more radical transformation than in OPKO's origins.)
The stock was down to $3 in the Summer of 1976 (it had been above $60 before the bear market in 1974)
But after the cassinos were approved in Atlantic City in November 1976, the stock which had been trading around $3 was up to $60 by June 1997 and then when its cassino opened it went to $200 in less than two days.
Can you possibly expect something like that happening using your "short technique"?

There is no question that OPKO is now one of the LARGEST SHORT TRAPS around.
And there could be a SHORT SQUEEZE or an STAMPEDE to COVER on any of the aforementioned "POSSIBLE NEWS"